Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

How Biotech Consultancy Services are Transforming Healthcare Innovations

Mar 29, 2025

The Role of Biotech Consultancy in Healthcare

The healthcare industry is continually evolving, driven by the need for more effective treatments, advanced technologies, and innovative solutions. Biotech consultancy services play a crucial role in this transformation, offering specialized expertise to help companies navigate the complex landscape of biotechnology. These consultancies provide valuable insights and strategic guidance, enabling healthcare companies to accelerate their innovation processes and improve patient outcomes.

Biotech consultants bring a wealth of knowledge and experience to the table, offering tailored solutions that address specific challenges faced by healthcare organizations. By leveraging their expertise, companies can streamline their research and development efforts, reduce time-to-market for new products, and enhance their competitive edge. This collaborative approach ensures that healthcare innovations are not only groundbreaking but also practical and feasible.

biotech laboratory

Accelerating Drug Development

One of the primary areas where biotech consultancy services make a significant impact is in drug development. The process of bringing a new drug to market is both time-consuming and costly, often taking years of research and millions of dollars in investment. Biotech consultants assist companies in optimizing each stage of drug development, from initial discovery and preclinical trials to regulatory approval and commercialization.

By providing expert advice on regulatory compliance, clinical trial design, and data analysis, consultants help ensure that new drugs meet the necessary standards and regulations. This not only speeds up the approval process but also minimizes the risk of costly delays or failures. As a result, patients gain access to innovative therapies more quickly, improving overall healthcare outcomes.

Enhancing Personalized Medicine

Personalized medicine is an emerging field that tailors medical treatments to individual patients based on their genetic makeup. Biotech consultancy services are pivotal in advancing this area by supporting the development of precision therapies and diagnostic tools. Consultants work with healthcare companies to identify biomarkers, design targeted therapies, and implement personalized treatment plans.

personalized medicine

This approach not only improves treatment efficacy but also reduces adverse effects by ensuring that patients receive therapies that are specifically suited to their unique genetic profiles. As a result, personalized medicine is transforming healthcare by offering more effective and safer treatment options.

Bridging the Gap Between Research and Market

Biotech consultancies act as a bridge between groundbreaking research and marketable products. They facilitate collaboration between research institutions, startups, and established pharmaceutical companies, fostering an environment of innovation. By connecting these entities, consultancies help translate cutting-edge research into viable healthcare solutions.

Moreover, biotech consultants assist in identifying potential partnerships and funding opportunities, enabling companies to secure the resources needed to bring their innovations to market. This strategic guidance ensures that promising discoveries do not remain confined to the lab but reach patients who can benefit from them.

medical research

Future Prospects and Challenges

As the biotech industry continues to grow, so too does the demand for consultancy services capable of navigating its complexities. The future holds exciting prospects for the integration of artificial intelligence, machine learning, and big data analytics into biotech innovations. Consultants will play a crucial role in harnessing these technologies to drive further advancements in healthcare.

However, challenges remain, including regulatory hurdles and ethical considerations. Biotech consultancies must address these issues head-on, ensuring that innovations are developed responsibly and with patient safety as a top priority. By doing so, they will continue to transform healthcare, paving the way for a healthier future.